Earnings

iRadimed Lowers FY2026 Adj EPS Guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 Est; Narrows FY2026 Sales Guidance from $91.000M-$96.000M to $91.600M-$93.100M vs $92.133M Est

Oct 30, 2026 · 08:33 AM ET· updated 1h ago

iRadimed (NASDAQ:IRMD) lowers FY2026 Adj EPS guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 analyst estimate. Narrows FY2026 sales outlook from $91.000 million-$96.000 million to $91.600 million-$93.100 million vs

Why It Matters

iRadimed made its sales forecast smaller and less rosy. When a company shrinks its own expectations, watch whether they can still hit the new, lower targets.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IRMD78.00

-7.74 (-9.03%)

MMM178.27

+0.91 (+0.51%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.